evok-defa14a_20171231.htm

0001564590-18-005960.txt : 20180316 0001564590-18-005960.hdr.sgml : 20180316 20180316093115 ACCESSION NUMBER: 0001564590-18-005960 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20180316 DATE AS OF CHANGE: 20180316 EFFECTIVENESS DATE: 20180316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 18694379 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 DEFA14A 1 evok-defa14a_20171231.htm DEFA14A evok-defa14a_20171231.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐	Preliminary Proxy Statement

☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐	Definitive Proxy Statement

☒	Definitive Additional Materials

☐	Soliciting Material under §240.14a-12

Evoke Pharma, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

Evoke pharma Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meetingto be held on April 26, 2018, for Evoke Pharma, Inc.This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. Weencourage you to access and review all of the important information contained in the proxy materials before voting. To view theproxy statement and annual report, go to www.proxydocs.com/evok. To submit your proxy while visiting this site, you will needthe 12 digit control number in the box below.Under new United States Securities and ExchangeCommission rules, proxy materials do not haveto be delivered in paper. Proxy materials canbe distributed by making them available on theInternet. We have chosen to use these proceduresfor our 2018 Annual Meeting and need YOURparticipation.If you want to receive a paper or e-mail copy ofthe proxy materials, you must request one. Thereis no charge to you for requesting a copy. In orderto receive a paper package in time for this year’sannual meeting, please make this request on orbefore April 13, 2018.Printed materials may be requested by one of the following methods:INTERNETwww.investorelections.com/evokYou must use the 12 digit control numberlocated in the shaded gray box below.TELEPHONE(866) 648-8133*E-MAILpaper@investorelections.com* If requesting material by e-mail, please senda blank e-mail with the 12 digit control number(located below) in the subject line. No otherrequests, instructions or other inquiries should beincluded with your e-mail requesting material.ACCOUNT NO. SHARESThe purpose of the Annual Meeting is to take action on the following proposals:The Board of Directors recommends that you vote “FOR” the following.1. Election of two directors for a three-year term to expire at the 2021 annual meeting of stockholdersNominees 01 Cam L. Garner; and02 Scott L. Glenn2. Ratification of the appointment of BDO USA, LLP as our independent Registered public accountants for the year ending December 31, 20183. Approval of the Amendment and Restatement of 2013 Equity Incentive Award Plan4. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.Date: Thursday, April 26, 2018Time: 8:30 a.m. (Local Time)Place: 12670 High Bluff Drive, San Diego, CA 92130Evoke pharma Company Notice of Annual MeetingProxy Materials Available to View or Receive:1. Proxy Statement 2. Annual ReportFor a Convenient Way to View Proxy Materials_ and _VOTE Online go to: www.proxydocs.com/evok